Singh Pawan Kumar, Shrestha Deepa Kumari, Singh Navneet, Gupta Nalini
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
BMJ Case Rep. 2020 Feb 28;13(2):e232607. doi: 10.1136/bcr-2019-232607.
Small cell lung cancer (SCLC) accounts for nearly 18% of lung cancer cases. Most of the patients of SCLC are not surgical candidates, due to advanced stage at presentation hence only viable options are chemotherapy and radiotherapy. Long-term survival in SCLC is extremely rare due to relapses and comorbidities. Ten-year survival has never been reported in cases with extensive disease at presentation and history of relapses. Here we are describing a case of extensive disease SCLC who has survived multiple relapses and has received five lines of systemic therapy apart from radiation and palliative care. This case emphasises on the need of active and strict disease surveillance at each follow-up.
小细胞肺癌（SCLC）占肺癌病例的近18%。大多数小细胞肺癌患者不适合手术，因为就诊时已处于晚期，因此唯一可行的选择是化疗和放疗。由于复发和合并症，小细胞肺癌的长期生存极为罕见。对于就诊时为广泛期疾病且有复发史的患者，从未有过十年生存的报道。在此，我们描述一例广泛期小细胞肺癌患者，该患者多次复发后存活，除放疗和姑息治疗外还接受了五线全身治疗。该病例强调了每次随访时积极、严格的疾病监测的必要性。
